FOI release

Freedom of Information request on access to documents for the product Stelara (Ustekinumab) (FOI 21/961, FOI 21/1021 and FOI 21/1066)

Published 17 January 2022

17th September 2021

FOI 21/961, FOI 21/1021 and FOI 21/1066

Dear

Thank you for your information request, dated 14th September which was logged as FOI 21/1066. Please note this request has been amalgamated with FOI 21/961 21/990 and 21/1021 due to them being substantially similar.

I can confirm that the MHRA does hold some of the information that you have requested. However, we have also determined that the information is exempt under Section 12 of the Freedom of Information Act and we cannot process your request any further.

Section 12 of the Act allows public authorities to refuse requests where the cost of dealing with them would exceed the appropriate limit. This represents the estimated cost of one person spending 24 working hours in determining whether the department holds the information, locating, retrieving and extracting the information.

In order to process your request, we would need to: retrieve and redact as appropriate the many files which have been requested. We consider that this would take longer than 24 working hours to complete.

Please note that substantially similar requests made within 60 working days of an original request can be aggregated into one for the purposes of calculating a cost limit, meaning that section 12 could still apply.

If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review would be carried out by a senior member of the Agency who was not involved with the original decision.

If you have a query about the information provided, please reply to this email.

Yours sincerely

MHRA Customer Service Centre

Medicines and Healthcare products Regulatory Agency

10 South Colonnade, Canary Wharf, London E14 4PU